A review examines kaempferol supplementation's impact on osteoarthritis, revealing limited clinical effectiveness.
Background: Kaempferol supplementation (KS) has been used in Iranian medicine to treat several conditions, including rheumatic diseases. Aim: To review the use of KS in rheumatic diseases. Methods: PubMed and Scielo databases were searched for articles on KS and rheumatic diseases until September 2024. Results: There are 3 articles with 162 patients. Age varied from 52 to 56.31 ± 8.90 years old, and female gender ranged from 32% to 100%. The kaempferol dosage went from 300 mg to 15 g/day. The study follow-up ranged from 4 to 8 weeks. Concerning outcomes, no significant clinical differences were detected comparing kaempferol and control. A reduction in proinflammatory parameters was observed after kaempferol supplementation: a decrease in tumor necrosis factor and matrix metalloproteinase-1 levels and an increase in interleukin-10. Conclusion: This review shows that KS does not seem to have a significant clinical impact on OA treatment. One study showed decreased cytokine levels and a reduction in metalloproteinase. Future studies are, however, needed to confirm the present data.
No takes yet. Share an insight, caveat, or question.
Lerner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: